Company intelligence / Profile preview

Myeloid Therapeutics

Ownership: Private
Employees: ~50
Development stage: Phase 1

Overview

Myeloid develops mRNA-immunotherapies combining LNP delivery with CAR engineering to activate myeloid cells against solid tumors. Clinical programs include MT-101 (anti-CD5 CAR) in PTCL and MT-302 (anti-TROP2 CAR) in epithelial cancers, with Fast Track designation received for MT-101.

Therapeutic areas: OncologyImmunology
Modalities: mRNA-based immunotherapiesCAR-T cell therapiesRNA-based gene editing
Industry: Biotech

Drug pipeline

17 assets

MT-101

16 more assets in the full pipeline.

Request access →

Partnerships

PRIME MedicineAcuitas TherapeuticsNew South Wales Government

Beyond the preview

Go deeper on Myeloid Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Myeloid Therapeutics.

Explore the full profile